Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 50Breast Neoplasms 50Carcinoma, Non-Small-Cell Lung 48Prostatic Neoplasms 47Squamous Cell Carcinoma of Head and Neck 37Lung Neoplasms 30Head and Neck Neoplasms 26Glioma 23Rectal Neoplasms 22Sarcoma 20Neoplasms 20Brain Neoplasms 20Oropharyngeal Neoplasms 16Esophageal Neoplasms 15Uterine Cervical Neoplasms 14Neoplasm Metastasis 14Astrocytoma 14Esophageal Squamous Cell Carcinoma 13Triple Negative Breast Neoplasms 12Carcinoma, Hepatocellular 12Pancreatic Neoplasms 11Melanoma 11Gliosarcoma 10Colorectal Neoplasms 10Stomach Neoplasms 9Small Cell Lung Carcinoma 9Lymphoma 9Hodgkin Disease 9Carcinoma, Squamous Cell 9Urinary Bladder Neoplasms 8

Interventions

tazemetostat 1osimertinib 1itacitinib 1Radiotherapy 1INCB039110 1AZD1390 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Inhibition, Psychological × Radiotherapy × 1 year × Clear all
NCT03423628 2025-12-22

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

AstraZeneca

Phase 1 Recruiting
180 enrolled
CNS

Brain Neoplasms, Glioblastoma, Inhibition, Psychological, Meningeal Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡